Acceleron Pharma | XLRN

Acceleron Pharma traded at $178.75 this Friday November 19th, decreasing $0 or 0 percent since the previous trading session. Looking back, over the last four weeks, Acceleron Pharma lost 3.62 percent. Over the last 12 months, its price rose by 57.43 percent. Looking ahead, we forecast Acceleron Pharma to be priced at 173.94 by the end of this quarter and at 160.28 in one year, according to Trading Economics global macro models projections and analysts expectations.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview

Acceleron Pharma
Acceleron Pharma Inc. is a biopharmaceutical company. The Company is focused on its research, development, and commercialization efforts in pulmonary and hematologic diseases. Its research is focused on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta) protein superfamily. The Company's product pipeline includes Sotatercept, ACE-1334 and REBLOZYL (luspatercept-aamt). Its lead pulmonary program, Sotatercept, is an activin receptor type IIA fusion protein that is used for the treatment of patients with pulmonary arterial hypertension (PAH). ACE-1334 is a wholly owned TGF-beta superfamily-based ligand trap designed to bind and inhibit TGF-beta 1 and 3 ligands but not TGF-beta 2. Its REBLOZYL (luspatercept-aamt), is an erythroid maturation agent designed to promote red blood cell (RBC).